Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Timothy Fitzgerald,1 Richard Melsheimer,2 Marie-Hélène Lafeuille,3 Patrick Lefebvre,3 Laura Morrison,3 Kimberly Woodruff,1 Iris Lin,1 Bruno Emond3 1Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA; 2Medical Affairs, Janssen Biolo...

Full description

Saved in:
Bibliographic Details
Main Authors: Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B
Format: article
Language:EN
Published: Dove Medical Press 2021
Subjects:
biosimilars
chronic inflammatory disease
treatment discontinuation
infliximab
treatment switching
Medicine (General)
R5-920
Online Access:https://doaj.org/article/fad32ee9734e4ce0b8c50a317d79e827
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items